Accidental Flibanserin Ingestion in Children Causing Acute Respiratory and Central Nervous System Depression: What Health Care Professionals Need to Know.

Abstract

Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville, Virginia Department of Psychiatry, University of California, San Diego School of Medicine, San Diego, the Department of Psychiatry and Neuroscience, University of California, Riverside, Riverside, and the Neuroscience Education Institute, San Diego, California Guidelines for Letters. Letters posing a question or challenge to an article appearing in Obstetrics & Gynecology should be submitted within 8 weeks of the article’s publication online. Letters received after 8 weeks will rarely be considered. Letters should not exceed 350 words, including signatures and 5 references. Letters will be published at the discretion of the Editor. The Editor may send the letter to the authors of the original paper so their comments may be published simultaneously. The Editor reserves the right to edit and shorten letters. Letters should be submitted using the Obstetrics & Gynecology online submission and review system, Editorial Manager (http://ong.edmgr.com). Financial Disclosure Dr. Clayton has served as a consultant to AbbVie Inc., Brii Biosciences, Fabre-Kramer, Field Trip Health, Janssen Research & Development, LLC, Mind Cure Health, Ovoca Bio PLC, Praxis Precision Medicines, PureTech Health, S1 Biopharma, Sage Therapeutics, Takeda/Lundbeck, Vella Bioscience, Inc., and WCG MedAvante-ProPhase. She has received grants from Daré Bioscience, Janssen, Praxis Precision Medicines, Relmada Therapeutics, Inc., and Sage Therapeutics. She holds royalties/copyrights with Ballantine Books/Random House, Changes in Sexual Functioning Questionnaire, and Guilford Publications. She holds shares/restricted stock units with Euthymics, Mediflix LLC, and S1 Biopharma. Dr. Stahl has served as a consultant to Acadia, Alkermes, Allergan, AbbVie, Axsome, Clearview, Eisai Pharmaceuticals, Gedeon Richter, Intra-Cellular Therapies, Karuna, Levo Therapeutics, Lundbeck, Merck, Neurocrine, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Taliaz, Teva, Tris Pharma, and VistaGen. He holds options in Genomind, Lipidio, and Delix. He has served on speakers bureaus for Acadia, Lundbeck, Otsuka, Perrigo, Servier, Sunovion, and Teva, and he has received research and/or grant support from Acadia, Allergan/AbbVie, Avanir, Braeburn Pharmaceuticals, Eisai, Eli Lilly, Harmony Biosciences, Indivior, Intra-Cellular Therapies, Ironshore, Neurocrine, Otsuka, Pear Therapeutics, Sage, Shire, Sunovion, Supernus, and Torrent. Editorial support for this Letter to the Editor was performed by Kayt Scott, PhD, Sarah A. Laredo, PhD, and Lauren Hummel, BA, each of Arbor Scientia, supported by Sprout Pharmaceuticals, Inc., according to Good Publication Practices (GPP3). All opinions, conclusions, and data interpretation lie with the authors. The authors have served in the past as consultants to Sprout but received no payment for writing this letter. Support for logistics was provided by Sprout to the agency Arbor Scientia.